[ Price : $8.95]
FDA grants Opna Bio an orphan drug designation for its investigational treatment OPN-2853 (zavabresib) for treating myelofibrosis.[ Price : $8.95]
A United States Pharmacopoeia study finds that protective purchasing following information on drug shortages can adversely affect ...[ Price : $8.95]
FDA issues a draft guidance detailing expectations for how makers of cuffless, non-invasive blood pressure monitoring devices shou...[ Price : $8.95]
Six King & Spalding attorneys analyze FDA advertising and promotion enforcement letters for drugs and medical devices issued in 20...[ Price : $8.95]
As its NDA is currently under FDA review, Corcept Therapeutics says its experimental drug relacorilant met the overall survival pr...[ Price : $8.95]
FDA releases the form FDA-483 with six observations from an inspection at the Lupin sterile manufacturing facility in Nagpur, Indi...[ Price : $8.95]
Cogent Biosciences says FDA has agreed to accept the companys planned NDA for cancer drug bezuclastinib under the agencys Real-Tim...[ Price : $8.95]
FDA says it will start accepting applications on 2/1 for its new PreCheck Pilot program intended to boost domestic drug manufactur...